Literature DB >> 18000686

Fenoldopam for acute kidney injury in children.

Chad A Knoderer1, Jeffrey D Leiser, Corina Nailescu, Mark W Turrentine, Sharon P Andreoli.   

Abstract

We report two cases of children with severe cardiomyopathy requiring treatment with ventricular assist devices who developed acute kidney injury and were treated with fenoldopam. Therapy with fenoldopam appeared successful in one case in that renal replacement therapy was avoided with improvement in urine output and renal function. These are the first reported cases of fenoldopam use in children with acute kidney injury receiving mechanical circulatory support.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000686     DOI: 10.1007/s00467-007-0659-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  16 in total

1.  Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group.

Authors:  R Bellomo; M Chapman; S Finfer; K Hickling; J Myburgh
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

Review 2.  Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension.

Authors:  M B Murphy; C Murray; G D Shorten
Journal:  N Engl J Med       Date:  2001-11-22       Impact factor: 91.245

Review 3.  Initial experience with fenoldopam in children.

Authors:  L M Strauser; R D Pruitt; J D Tobias
Journal:  Am J Ther       Date:  1999-09       Impact factor: 2.688

4.  Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial.

Authors:  Tiziana Bove; Giovanni Landoni; Maria Grazia Calabrò; Giacomo Aletti; Giovanni Marino; Elisa Cerchierini; Giuseppe Crescenzi; Alberto Zangrillo
Journal:  Circulation       Date:  2005-06-21       Impact factor: 29.690

5.  Outcome of patients with ventricular assist devices and acute renal failure requiring renal replacement therapy.

Authors:  B Kaltenmaier; W Pommer; F Kaufmann; E Hennig; M Molzahn; R Hetzer
Journal:  ASAIO J       Date:  2000 May-Jun       Impact factor: 2.872

6.  The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects.

Authors:  V S Mathur; S K Swan; L J Lambrecht; S Anjum; J Fellmann; D McGuire; M Epstein; R R Luther
Journal:  Crit Care Med       Date:  1999-09       Impact factor: 7.598

7.  Fenoldopam for controlled hypotension during spinal fusion in children and adolescents.

Authors:  J D Tobias
Journal:  Paediatr Anaesth       Date:  2000       Impact factor: 2.556

8.  Outcomes of children bridged to heart transplantation with ventricular assist devices: a multi-institutional study.

Authors:  Elizabeth D Blume; David C Naftel; Heather J Bastardi; Brian W Duncan; James K Kirklin; Steven A Webber
Journal:  Circulation       Date:  2006-05-16       Impact factor: 29.690

9.  Use of fenoldopam to increase urine output in a patient with renal insufficiency secondary to septic shock: A case report.

Authors:  Brady S Moffett; Renán Orellana
Journal:  Pediatr Crit Care Med       Date:  2006-11       Impact factor: 3.624

10.  Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function.

Authors:  N H Shusterman; W J Elliott; W B White
Journal:  Am J Med       Date:  1993-08       Impact factor: 4.965

View more
  3 in total

Review 1.  The management of hypertensive emergencies in children after stem cell transplantation.

Authors:  D G Horn; M N Trame; G Hempel
Journal:  Int J Clin Pharm       Date:  2011-03-12

Review 2.  Management of acute kidney injury in children: a guide for pediatricians.

Authors:  Sharon P Andreoli
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 3.  Acute kidney injury in children.

Authors:  Sharon Phillips Andreoli
Journal:  Pediatr Nephrol       Date:  2008-12-13       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.